PUBLISHER: The Business Research Company | PRODUCT CODE: 1477067
PUBLISHER: The Business Research Company | PRODUCT CODE: 1477067
Animal testing or in-vivo testing is the use of living animals in scientific experiments to assess the safety and effectiveness of new products developed in the biopharma, medical devices, chemicals, food and other industries. Animal testing allows scientists to understand how the human body might react to specific substances. The study on animals is a vital part of the research because the basic cell process and physiology of animals is similar to that of humans.
The animal testing market consists of the total expenses incurred by end-use entities that use animals for testing their products. End-use entities include academic research institutions and various industries (such as pharmaceuticals, medical devices, chemicals & pesticides and cosmetics,) that conduct animal testing during product development. Pharmaceutical and medical device companies also use animal testing to understand basic disease mechanisms. End-use entities may also outsource these tests to clinical research organizations (CROs). The animal testing market covered in this report includes sales of animal testing services by CROs to end use industries.
The Global animal testing market grew to $12.19 billion in 2023 at a compound annual growth rate (CAGR) of more than 2.0%.
Increasing Investment In R&D By The Pharmaceutical Companies
The rise in investment in R&D (research and development) by the pharma companies leads to the growth of the animal testing market. The rate of investment has been increasing over the years and pharmaceutical companies are the top investors in R&D. The key factor for research-based pharmaceutical companies investing more in R&D is the discovery and development of new drugs serving unmet medical needs. For FY20-21, the average R&D expenses of pharma companies in India were 7.2% of total revenues, with Lupin, Alembic Pharma and Dr. Reddy's spending more than others. The top 20 global pharmaceutical companies collectively spent $139 billion on R&D in 2022. Roche, a Swiss healthcare company, spent 14.05 billion Swiss francs ($15.15 billion) on R&D in 2022. For example, the global pharmaceutical companies collectively spent $139 billion on research and development in 2022. Also in 2019, globally pharmaceutical companies spent an average of roughly 25% of their revenue on R&D, according to federal government statistics. Therefore, the increasing investment in animal models will be widely employed in pharmaceutical research. This is expected to drive the animal testing market.
AI To Accelerate Drug Discovery Technologies With Ethical Alternatives
Major non-animal testing technologies companies are focusing on AI (artificial intelligence) to accelerate drug discovery technologies with ethical alternatives to expand their businesses. AI plays a crucial role in enhancing the capabilities of both animal testing and non-animal alternative testing methods, ultimately advancing biomedical research while reducing the ethical concerns and limitations associated with animal experimentation. For example, in June 2023, Quantiphi, a US-based AI-driven digital engineering company, launched Digital Animal Replacement Technology (DART), which is a solution that offers a humane and accurate alternative to traditional animal testing for drug discovery, manufacturing and pre-clinical trials. DART combines human biology with advanced digital technologies to predict drug safety and efficacy accurately, eliminating the need for animal testing in many scenarios. The technology uses ethically sourced human stem cells, a Digital Workstation and AI to accelerate drug discovery while ensuring safety and efficacy. DART's launch represents a significant step towards more ethical, efficient and effective alternatives to animal testing in the pharmaceutical industry.
The global non-animal alternatives testing market is fairly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up to 10.95% of the total market in 2022.
Animal Testing And Non-Animal Alternative Testing Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global animal testing and non-animal alternative testing market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market for animal testing and non-animal alternative testing? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The animal testing and non-animal alternative testing market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider animal testing and non-animal alternative testing market; and compares it with other markets.
Non-Animal Alternative Testing Trends- This chapter describes the major trends shaping the global non-animal alternative testing market.